Basics Novavax, Inc. Novavax Inc is a clinical-stage vaccine company. It is engaged in the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. IPO Date: December 13, 1995 Sector: Healthcare Industry: Biotech Market Cap: $1.12B Activated in VL: True Average Daily Range Avg Daily Range: $0.81 | 3.60% Avg Daily Range (30 D): $0.15 | 2.06% Avg Daily Range (90 D): $0.20 | 2.50% Institutional Daily Volume Avg Daily Volume: 3.99M Avg Daily Volume (30 D): 3.43M Avg Daily Volume (90 D): 5.01M Trade Size Avg Trade Size (Sh.): 195 Avg Trade Size (Sh.) (30 D): 141 Avg Trade Size (Sh.) (90 D): 158 Institutional Trades Total Inst.Trades: 8,766 Avg Inst. Trade: $3.51M Avg Inst. Trade (30 D): $1.67M Avg Inst. Trade (90 D): $1.86M Avg Inst. Trade Volume: .1M Avg Inst. Trades (Per Day): 3 Market Closing Trades Avg Closing Trade: $6.63M Avg Closing Trade (30 D): $2.11M Avg Closing Trade (90 D): $2.5M Avg Closing Volume: 227.44K     News Sep 26, 2025 @ 4:08 AM Robert F. Kennedy Jr. Faces Impeachment Push From ... Source: Vishaal Sanjay Sep 10, 2025 @ 5:21 PM FDA Moves To Publicize Data On Pregnant Women's Co... Source: Vandana Singh Aug 12, 2025 @ 5:41 PM CDC Shooting Linked To Suspect's COVID-19 Vaccine ... Source: Vandana Singh Jun 30, 2025 @ 1:51 PM Moderna's mRNA Flu Vaccine Outperforms Standard Sh... Source: Vandana Singh Jun 29, 2025 @ 6:08 PM Vaccine Adjuvants Market to Reach USD 5.43 Billion... Source: Sns Insider Financials   TTM Q3 2025 Q2 2025 Basic EPS $2.11 $-1.25 $.66 Diluted EPS $1.78 $-1.25 $.62 Revenue $ 1.06B $ 70.45M $ 239.24M Gross Profit $ 977.05M $ 48.95M $ 223.92M Net Income / Loss $ 341.75M $ -202.38M $ 106.51M Operating Income / Loss $ 307.49M $ -178.02M $ 101.07M Cost of Revenue $ 87.61M $ 21.5M $ 15.33M Net Cash Flow $ -305.23M $ 14.38M $ -9.5M PE Ratio 3.83     Splits May 10, 2019:   1:20